These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 21466737)

  • 1. Adjusting diet with sapropterin in phenylketonuria: what factors should be considered?
    MacDonald A; Ahring K; Dokoupil K; Gokmen-Ozel H; Lammardo AM; Motzfeldt K; Robert M; Rocha JC; van Rijn M; Bélanger-Quintana A
    Br J Nutr; 2011 Jul; 106(2):175-82. PubMed ID: 21466737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy, safety and population pharmacokinetics of sapropterin in PKU patients <4 years: results from the SPARK open-label, multicentre, randomized phase IIIb trial.
    Muntau AC; Burlina A; Eyskens F; Freisinger P; De Laet C; Leuzzi V; Rutsch F; Sivri HS; Vijay S; Bal MO; Gramer G; Pazdírková R; Cleary M; Lotz-Havla AS; Munafo A; Mould DR; Moreau-Stucker F; Rogoff D
    Orphanet J Rare Dis; 2017 Mar; 12(1):47. PubMed ID: 28274234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recommendations for evaluation of responsiveness to tetrahydrobiopterin (BH(4)) in phenylketonuria and its use in treatment.
    Levy H; Burton B; Cederbaum S; Scriver C
    Mol Genet Metab; 2007 Dec; 92(4):287-91. PubMed ID: 18036498
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term follow-up and outcome of phenylketonuria patients on sapropterin: a retrospective study.
    Keil S; Anjema K; van Spronsen FJ; Lambruschini N; Burlina A; Bélanger-Quintana A; Couce ML; Feillet F; Cerone R; Lotz-Havla AS; Muntau AC; Bosch AM; Meli CA; Billette de Villemeur T; Kern I; Riva E; Giovannini M; Damaj L; Leuzzi V; Blau N
    Pediatrics; 2013 Jun; 131(6):e1881-8. PubMed ID: 23690520
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Introduction of sapropterin dihydrochloride as standard of care in patients with phenylketonuria.
    Vernon HJ; Koerner CB; Johnson MR; Bergner A; Hamosh A
    Mol Genet Metab; 2010 Jul; 100(3):229-33. PubMed ID: 20418136
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recommendations for the use of sapropterin in phenylketonuria.
    Cunningham A; Bausell H; Brown M; Chapman M; DeFouw K; Ernst S; McClure J; McCune H; O'Steen D; Pender A; Skrabal J; Wessel A; Jurecki E; Shediac R; Prasad S; Gillis J; Cederbaum S
    Mol Genet Metab; 2012 Jul; 106(3):269-76. PubMed ID: 22575621
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term efficacy and safety of sapropterin in patients who initiated sapropterin at < 4 years of age with phenylketonuria: results of the 3-year extension of the SPARK open-label, multicentre, randomised phase IIIb trial.
    Muntau AC; Burlina A; Eyskens F; Freisinger P; Leuzzi V; Sivri HS; Gramer G; Pazdírková R; Cleary M; Lotz-Havla AS; Lane P; Alvarez I; Rutsch F
    Orphanet J Rare Dis; 2021 Aug; 16(1):341. PubMed ID: 34344399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. International best practice for the evaluation of responsiveness to sapropterin dihydrochloride in patients with phenylketonuria.
    Muntau AC; Adams DJ; Bélanger-Quintana A; Bushueva TV; Cerone R; Chien YH; Chiesa A; Coşkun T; de Las Heras J; Feillet F; Katz R; Lagler F; Piazzon F; Rohr F; van Spronsen FJ; Vargas P; Wilcox G; Bhattacharya K
    Mol Genet Metab; 2019 May; 127(1):1-11. PubMed ID: 31103398
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sapropterin. Phenylketonuria: for a minority of patients.
    Prescrire Int; 2010 Jun; 19(107):101-4. PubMed ID: 20738029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sapropterin: a review of its use in the treatment of primary hyperphenylalaninaemia.
    Sanford M; Keating GM
    Drugs; 2009; 69(4):461-76. PubMed ID: 19323589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimizing the use of sapropterin (BH(4)) in the management of phenylketonuria.
    Blau N; Bélanger-Quintana A; Demirkol M; Feillet F; Giovannini M; MacDonald A; Trefz FK; van Spronsen FJ
    Mol Genet Metab; 2009 Apr; 96(4):158-63. PubMed ID: 19208488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adherence to tetrahydrobiopterin therapy in patients with phenylketonuria.
    Rohr F; Wessel A; Brown M; Charette K; Levy HL
    Mol Genet Metab; 2015 Jan; 114(1):25-8. PubMed ID: 25467057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of sapropterin in the management of phenylketonuria: seven case reports.
    Gokmen Ozel H; Lammardo AM; Motzfeldt K; Robert M; Rocha JC; van Rijn M; Ahring K; Bélanger-Quintana A; MacDonald A; Dokoupil K
    Mol Genet Metab; 2013 Feb; 108(2):109-11. PubMed ID: 23266371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sapropterin dihydrochloride for the treatment of hyperphenylalaninemias.
    Blau N
    Expert Opin Drug Metab Toxicol; 2013 Sep; 9(9):1207-18. PubMed ID: 23705856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of sapropterin dihydrochloride (tetrahydrobiopterin, 6R-BH4) for reduction of phenylalanine concentration in patients with phenylketonuria: a phase III randomised placebo-controlled study.
    Levy HL; Milanowski A; Chakrapani A; Cleary M; Lee P; Trefz FK; Whitley CB; Feillet F; Feigenbaum AS; Bebchuk JD; Christ-Schmidt H; Dorenbaum A;
    Lancet; 2007 Aug; 370(9586):504-10. PubMed ID: 17693179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Individualized long-term outcomes in blood phenylalanine concentrations and dietary phenylalanine tolerance in 11 patients with primary phenylalanine hydroxylase (PAH) deficiency treated with Sapropterin-dihydrochloride.
    Stockler-Ipsiroglu S; Yuskiv N; Salvarinova R; Apatean D; Ho G; Cheng B; Giezen A; Lillquist Y; Ueda K
    Mol Genet Metab; 2015 Mar; 114(3):409-14. PubMed ID: 25497838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spotlight on sapropterin in primary hyperphenylalaninemia.
    Sanford M; Keating GM
    BioDrugs; 2009; 23(3):201-2. PubMed ID: 19627172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term comparative effectiveness of pegvaliase versus standard of care comparators in adults with phenylketonuria.
    Zori R; Ahring K; Burton B; Pastores GM; Rutsch F; Jha A; Jurecki E; Rowell R; Harding C
    Mol Genet Metab; 2019; 128(1-2):92-101. PubMed ID: 31439512
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of sapropterin dihydrochloride in increasing phenylalanine tolerance in children with phenylketonuria: a phase III, randomized, double-blind, placebo-controlled study.
    Trefz FK; Burton BK; Longo N; Casanova MM; Gruskin DJ; Dorenbaum A; Kakkis ED; Crombez EA; Grange DK; Harmatz P; Lipson MH; Milanowski A; Randolph LM; Vockley J; Whitley CB; Wolff JA; Bebchuk J; Christ-Schmidt H; Hennermann JB;
    J Pediatr; 2009 May; 154(5):700-7. PubMed ID: 19261295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sapropterin therapy increases stability of blood phenylalanine levels in patients with BH4-responsive phenylketonuria (PKU).
    Burton BK; Bausell H; Katz R; Laduca H; Sullivan C
    Mol Genet Metab; 2010; 101(2-3):110-4. PubMed ID: 20638313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.